bluebird bio, TC BioPharm to develop Gamma Delta CAR T cell product candidates for cancer immunotherapy
bluebird bio and Scottish immunotherapy company TC BioPharm have partnered and signed a license agreement on gamma delta CAR T cells.
Related Biotechnology, Pharmaceutical and Healthcare News
Original Article: bluebird bio, TC BioPharm to develop Gamma Delta CAR T cell product candidates for cancer immunotherapy
NEXT ARTICLE
More From BioPortfolio on "bluebird bio, TC BioPharm to develop Gamma Delta CAR T cell product candidates for cancer immunotherapy"